Overview

* Black Diamond Q3 net loss narrows to $8.5 mln from $15.6 mln last year

* Company's cash position at $135.5 mln, sufficient to fund operations into Q4 2027

* R&D expenses decreased due to workforce efficiencies and outlicensing

Outlook

* Company plans to release ORR and treatment duration data for silevertinib this quarter

* Black Diamond expects FDA feedback on silevertinib path in H1 2026

* Company has cash to fund operations into Q4 2027

Result Drivers

* R&D EXPENSES - Decrease in R&D expenses attributed to workforce efficiencies and outlicensing of BDTX-4933

* G&A EXPENSES - Reduction in G&A expenses due to restructuring efforts

* SILEVERTINIB DEVELOPMENT - Focus on silevertinib development in NSCLC and GBM, with upcoming clinical data releases

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$8.50

Income mln

Q3 Basic -$0.15

EPS

Q3 Cash $135.50

& mln

Investme

nts

Q3 -$10.98

Income mln

From

Operatio

ns

Q3 $10.98

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Black Diamond Therapeutics Inc ( BDTX ) is $9.00, about 57% above its November 5 closing price of $3.87

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)